Phase II Combination Stem Cell Therapy for the Treatment of Severe Coronary Ischemia(CI)
- Quick Summary of Findings: Study done to observe if infusing stem cells from a patient’s bone marrow would promote new blood vessels forming in patients with symptomatic severe coronary ischemia(CI). Study will determine if the treatment is safe, feasible and has an outcome of developing mature vessels leading to improved cardiac function
- Summary for a possible patient: Patients with severe heart vessel blockage may see improved health outcomes using treatment using stem cells to create/repair vessels and improve blood flow.
- Study Participants: Ages 18-80, have chronic coronary artery disease in at least 1 epicardial vessel
Mobilization of Endothelial Progenitor Cells and Aspirin (TROPHIC 3)
- Quick Summary of Findings: Study done to determine if using Aspirin during heart attacks inhibits the ability of endothelial progenitor cells(EPCs) from mobilizing. Aspirn is currently part of the standard of care when managing heart attacks and this study wants to determine at what dosage amount dose Aspirin negatively affect progenitor cells ability to repair. Findings showed that Aspirin decreases the number of EPCs in the body and impedes it’s adhesive ability.
- Summary for a possible patient: When receiving treatment for a heart attack, communicate with your doctor regarding how much Aspirin you may receive and if that is the appropriate form of treatment for your condition.
- Study Participants: Ages 18-80, have hypertrophic obstructive cardiomyopathy
- Source:https://clinicaltrials.gov/ct2/show/study/NCT02674958?term=stem+cell&cond=Heart+Valve+Diseases&phase=123&draw=2&rank=1 , https://www.ncbi.nlm.nih.gov/pubmed/16539843?dopt=Abstract
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure. (DREAM HF-1)
- Quick Summary of Findings: Study done to determine if transendocardial delivery of progenitor cells from bone-marrow is effective at treating chronic heart failure due to LV systolic dysfunction.
- Summary for a possible patient: For patients with issues that prevent their heart from pumping blood properly, treatment using cells from bone marrow may be a possible solution to improve one’s condition.
- Study Participants: Ages 18-80, has chronic HF of ischemic or nonischemic etiology.
- Source:https://clinicaltrials.gov/ct2/show/study/NCT02032004?term=stem+cell&cond=Heart+Failure%2C+Systolic&phase=123&draw=2&rank=1 , https://www.ncbi.nlm.nih.gov/pubmed/31318648?dopt=Abstract
Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS) (ELPIS)
- Quick Summary of Findings: Study designed to observe the safeness, tolerability and efficacy of longeveron mesenchymal stem cells (LMSCs) used as supplemental therapy to the standard Bidirectional cavopulmonary anastomosis (BDCPA) surgery for patients with Hypoplastic Left Heart Syndrome. The study is still in progress.
- Summary for a possible patient: Supplemental treatment using stem cells may be beneficial to those born with Hypoplastic Left Heart Syndrome in terms of improving heart health and functionality.
- Study Participants: Patients with Hypoplastic Left Heart Syndrome(HLHS) that requires Bidirectional cavopulmonary anastomosis (BDCPA) surgery.
Bone marrow derived adult stem cells for Chronic Heart Failure (Regen-IHD)
- Quick Summary of Findings: Study was done to determine if stem & progenitor cells from bone marrow effectively improved cardiac function and reduced symptoms for patients with heart failure. It is hypothesized that administering these cells will lead to increased circulation of progenitor and stem cells.
- Summary for a possible patient: Treatment using a combination of progenitor and stem cells from bone marrow may prove effective at improving health outcomes for those with heart failure issues.
- Study Participants: Ages 18+, patients diagnosed with heart failure secondary to ischaemic heart disease have been considered for a defibrillator implant.
Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease
- Quick Summary of Findings: The goal of this international study was to determine the efficacy of directly injecting Cardiology Stem Cell Centre adipose derived stem cells (CSCC_ASCs) in patients with reduced left ventricular Ejection Fraction(EF) and heart failure.
- Summary for a possible patient: Stem cells derived from fat tissue may be useful at improving health for those with heart failure or issues with their ability to pump blood.
- Study Participants: Ages 30-80 with chronic stable ischemic heart disease.
- Source: https://clinicaltrials.gov/ct2/show/record/NCT02673164?term=progenitor+cell&recrs=ade&cond=Heart+Failure&phase=123&draw=2&rank=5
Cell-Wave Study: Combined Extracorporal Shock Wave Therapy and Intracoronary Cell Therapy in Chronic Ischemic Myocardium
- Quick Summary of Findings: Study done to show if shock wave therapy performed before cell therapy improves the ability to extract progenitor cells in patients with chronic heart disease. Shock wave therapy may accelerate the growth factor to create bone marrow derived progenitor cells.
- Summary for a possible patient: For patients considering undergoing cell therapy having shock wave therapy done before cell therapy may increase the likelihood that a larger sample of progenitor/stem cells can be collected for therapy.
- Study Participants: Ages 18-80 with chronic ischemic heart disease and anterior myocardial infarction for over 3 months.
- Source: https://clinicaltrials.gov/ct2/show/record/NCT00326989?term=progenitor+cell&recrs=ade&cond=Heart+Failure&phase=123&draw=2&rank=9
Stem Cell Therapy in Advanced Heart Failure
- Quick Summary of Findings: Therapy using stem cells could be effective for patients with advanced heart failure that are currently receiving treatment via an internal cardiovertor with a defibrillator (ICD). Essentially the study reviewed if stem cell treatment reduced hospitalization rates and improved health outcomes.
- Summary for a possible patient: For those with advanced heart failure speak with your doctor to determine if stem cell treatment is applicable to you. Especially if the treatment you currently receive is ineffective.
- Study Participants: Ages 18+, patients with heart failure post coronary artery disease, those with previous surgery on arteries.
- Source: https://clinicaltrials.gov/ct2/show/NCT02871466?term=progenitor+cell&recrs=ade&cond=Heart+Failure&phase=123&draw=2&rank=4